Short answer
Kyverna Therapeutics Inc (KYTX) filed an 8-K current report with the SEC on February 24, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events). Two new directors appointed Feb 24, 2026: Andrew Miller (Class III, Karuna Therapeutics founder, led $14B BMS acquisition) and Sravan Emany (Class I, current CFO of Beam Therapeutics).
Kyverna Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Two new directors appointed Feb 24, 2026: Andrew Miller (Class III, Karuna Therapeutics founder, led $14B BMS acquisition) and Sravan Emany (Class I, current CFO of Beam Therapeutics)
- Both receive identical equity grants: $262,000 in options (1/36th monthly vesting) and $87,500 in RSUs (1/3rd annual vesting), with full acceleration on Change in Control
- Miller cash comp: $40K board + $10K Audit + $7.5K Science & Technology annually; Emany: $40K board + $20K Audit Chair + $5K N&CG annually
- Daniel Spiegelman resigned Feb 24, 2026 with no disagreement noted: board change appears routine replacement, not governance conflict
- Miller and Emany bring biopharma M&A and capital markets credibility: signals potential strategic/financing activity ahead for KYTX
Item 8.01 · Other Events
- Press release issued Feb 24, 2026 announcing two new Board appointments: Dr. Miller and Mr. Emany
- Board expansion signals potential strategic or governance shift at clinical-stage cell therapy company KYTX
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Get the next KYTX 8-K as it lands
Follow KYTX for push alerts, or ask the research agent what this filing means.